O(100GeV)\mathscr{O}(100 GeV) Deci-weak W′/Z′W^\prime/Z^\prime at Tevatron and LHC

Recently Tevatron released their measurements on invariant mass spectrum of electron/positron, as well as the di-jet arising from WW+WZ production with one W leptonically decay. Though the statistics is not significant, there are two bumps around 240 GeV and 120-160 GeV respectively. We proposed that the two bumps correspond to the extra light gauge bosons $Z^\prime$ and $W^\prime$, which couple with quarks with the deci-weak strength. In this brief report, we also simulated di-jet invariant mass distribution at the current running LHC.Comment: 8 pages, 3 EPS figures, ref added, figures update

New Color-Octet Vector Boson Revisit

Motivated by CDF recent measurements on di-jet invariant mass spectrum where di-jet is associated production with charged leptons ($e/\mu$) and missing energy, we re-examine the previous proposed massive color-octet axial-vector-like boson $Z_c$. Our simulation showed that the di-jet bump around 120-160 GeV can be induced by $Z_c$ with effective coupling $g_{Z_c q \bar q} =0.2 g_s$ (q represents the quark other than top and $g_s$ is the strong coupling constant). Moreover our numerical investigation indicated that the top quark forward-backward asymmetry $A_{FB}^t$ can be reproduced without distorting shape of differential cross section $d\sigma/d M_{t\bar t}$, provided that the $Z_c$ and top quark coupling is appropriately chosen ($g_{Z_c t \bar t} \simeq 4.5 g_{Z_c q \bar q}$). Our results also showed that the theoretical $A_{FB}^t$ as functions of $\Delta y$ and $M_{t\bar t}$ can be consistent with data within $1\sigma$ and $1.8\sigma$ respectively.Comment: 8 pages, 3 EPS figure

Adversarial Noise Layer: Regularize Neural Network By Adding Noise

In this paper, we introduce a novel regularization method called Adversarial Noise Layer (ANL) and its efficient version called Class Adversarial Noise Layer (CANL), which are able to significantly improve CNN's generalization ability by adding carefully crafted noise into the intermediate layer activations. ANL and CANL can be easily implemented and integrated with most of the mainstream CNN-based models. We compared the effects of the different types of noise and visually demonstrate that our proposed adversarial noise instruct CNN models to learn to extract cleaner feature maps, which further reduce the risk of over-fitting. We also conclude that models trained with ANL or CANL are more robust to the adversarial examples generated by FGSM than the traditional adversarial training approaches

4-{(Z)-(sec-Butyl­amino)(phen­yl)methyl­ene}-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one

In the title compound, C21H23N3O, the dihedral angles formed by the pyrazolone ring with two phenyl rings are 10.38 (8) and 76.94 (6)°. The sec-butyl­amino group is disordered over two positions, with refined site-occupancy factors of 0.730 (4) and 0.270 (4). The compound could potentially be ligand stabilized in the solid state in a keto–enamine tautomeric form. The amine functionality is involved in an intra­molecular N—H⋯O hydrogen bond, while weak inter­molecular C—H⋯O and C—H⋯N hydrogen bonds participate in the formation of the crystal structure

Diethyl 2,2-bis­(3,5-di-tert-butyl-4-hy­droxy­benz­yl)malonate

The title mol­ecule, C37H56O6, possesses twofold symmetry, with the twofold axis passing through the quaternary C atom. In the crystal, neighbouring mol­ecules are linked via O—H⋯O hydrogen bonds involving the phenol OH group and the carbonyl O atom, forming chains propagating in [101]. Within these chains, rings are formed with an R 2 2(20) motif. There are also C—H⋯O inter­actions present within the rings

Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy

BACKGROUND: Improving the HBe seroconversion rate of patients without HBeAg loss after long-term lamivudine therapy has become an urgent clinical problem that we have to face. Unfortunately, there is no consensus on the mananement of these patients. The aim of this study was to evaluate the efficacy of pegylated interferon (PEG-IFN) α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy. METHODS: Fifty patients with chronic hepatitis B without the loss of HBeAg after ≥96 weeks of lamivudine treatment were enrolled to withdraw from treatment to induce a biochemical breakthrough. Patients who achieved a biochemical breakthrough within 24 weeks received 48-weeks of PEG-IFN α2a therapy, and were then assessed during a subsequent 24-week follow-up period. RESULTS: Forty-three (86.0%) patients achieved a biochemical breakthrough within 24 weeks of lamivudine withdrawal. The rates of combined response (both undetectable HBV DNA and HBeAg loss) and HBsAg loss were alone 51.2% and 20.9%, respectively after 48 weeks of PEG-IFN α2a therapy, and 44.2% and 18.6%, respectively, at 24 weeks after treatment cessation. The end-of-treatment combined response rate was 65.4% among patients with a baseline HBsAg <20,000 IU/mL, which was significantly higher than 29.4% of patients with HBsAg ≥20,000 IU/mL (P=0.031). For patients with HBsAg levels <1,500 IU/mL at 12 and 24 weeks therapy, the end-of-treatment combined response rate was 68.2% and 69.0%, which were both significantly higher than patients with HBsAg ≥1,500 IU/mL (33.3% and 14.3%; P=0.048 and 0.001). The end-of-treatment combined response rate was significantly higher among patients with HBV DNA<10(5) copies/mL (76.2%) compared to patients with HBV DNA ≥10(5) copies/mL (27.3%) after 24 weeks of therapy (P=0.004). CONCLUSION: Retreatment with PEG-IFN α2a was effective and safe for patients without HBeAg loss after the withdrawal of long-term lamivudine therapy. HBsAg levels at the baseline, 12 and 24 weeks of therapy, and HBV DNA levels at 24 weeks of therapy, can predict the effect of PEG-IFN α2a after 48 weeks of therapy

(4Z)-4-[(4-Methoxy­benzyl­amino)(phen­yl)methyl­ene]-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one

In the title compound, C25H23N3O2, the dihedral angles formed by the pyrazolone ring with the three aromatic rings are 14.59 (7), 79.35 (5) and 87.10 (6)°. Three intra­molecular C—H⋯O, C—H⋯N and N—H⋯O hydrogen-bond inter­actions are present. The crystal structure is stabilized by two weak inter­molecular C—H⋯O and C—H⋯N hydrogen-bond inter­actions

Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.

Yes-associated protein (YAP) is a main mediator of the Hippo pathway and promotes cancer development and progression in human lung cancer. We sought to determine whether inhibition of YAP suppresses metastasis of human lung adenocarcinoma in a murine model. We found that metastatic NSCLC cell lines H2030-BrM3(K-rasG12C mutation) and PC9-BrM3 (EGFRΔexon19 mutation) had a significantly decreased p-YAP(S127)/YAP ratio compared to parental H2030 (K-rasG12C mutation) and PC9 (EGFRΔexon19 mutation) cells (P&nbsp;&lt;&nbsp;.05). H2030-BrM3 cells had significantly increased YAP mRNA and expression of Hippo downstream genes CTGF and CYR61 compared to parental H2030 cells (P&nbsp;&lt;&nbsp;.05). Inhibition of YAP by short hairpin RNA (shRNA) and small interfering RNA (siRNA) significantly decreased mRNA expression in downstream genes CTGF and CYR61 in H2030-BrM3 cells (P&nbsp;&lt;&nbsp;.05). In addition, inhibiting YAP by YAP shRNA significantly decreased migration and invasion abilities of H2030-BrM3 cells (P&nbsp;&lt;&nbsp;.05). We are first to show that mice inoculated with YAP shRNA-transfected H2030-BrM3 cells had significantly decreased metastatic tumour burden and survived longer than control mice (P&nbsp;&lt;&nbsp;.05). Collectively, our results suggest that YAP plays an important role in promoting lung adenocarcinoma brain metastasis and that direct inhibition of YAP by shRNA suppresses H2030-BrM3 cell brain metastasis in a murine model

Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model.

Human non‑small cell lung cancer (NSCLC) is associated with an extremely poor prognosis especially for the 40% of patients who develop brain metastasis, and few treatment strategies exist. Cucurbitacin E (CuE), an oxygenated tetracyclic triterpenoid isolated from plants particularly of the family Cucurbitaceae, has shown anti‑tumorigenic properties in several types of cancer, yet the mechanism remains unclear. Yes‑associated protein (YAP), a main mediator of the Hippo signaling pathway, promotes tumorigenesis, drug resistance and metastasis in human NSCLC. The present study was designed to ascertain whether CuE inhibits YAP and its downstream gene expression in the human NSCLC cell lines H2030‑BrM3 (K‑rasG12C mutation) and PC9‑BrM3 (EGFRΔexon19 mutation), which have high potential for brain metastasis. The efficacy of CuE in suppressing brain metastasis of H2030‑BrM3 cells in a murine model was also investigated. It was found that after CuE treatment in H2030‑BrM3 and PC9‑BrM3 cells, YAP protein expression was decreased, and YAP signaling GTIIC reporter activity and expression of the downstream genes CTGF and CYR61 were significantly (P&lt;0.01) decreased. CuE treatment also reduced the migration and invasion abilities of the H2030‑BrM3 and PC9‑BrM3 cells. Finally, our in vivo study showed that CuE treatment (0.2 mg/kg) suppressed H2030‑BrM3 cell brain metastasis and that mice treated with CuE survived longer than the control mice treated with 10% DMSO (P=0.02). The present study is the first to demonstrate that CuE treatment inhibits YAP and the signaling downstream gene expression in human NSCLC in vitro, and suppresses brain metastasis of NSCLC in a murine model. More studies to verify the promising efficacy of CuE in inhibiting brain metastasis of NSCLC and various other cancers may be warranted

4,6-Bis[4-(benzyl­sulfan­yl)styr­yl]-2-(methyl­sulfan­yl)pyrimidine

The title compound, C35H30N2S3, has been synthesized by a solvent-free reaction. The mol­ecule exhibits an E,E configuration, the benzene rings and pyrimidine rings being located on the opposite sides of the C=C bonds. The centroid–centroid separation of 3.5808 (17) Å indicates the existence of π–π stacking between nearly parallel pyrimidine and benzene rings of adjacent mol­ecules